Metastatic Colorectal Cancer

In this video, Michael Cecchini, MD, discusses “practice-changing” data from the CheckMate 8HW study, which were presented at ASCO Gastrointestinal Cancers Symposium.

The FDA granted an encorafenib-led combination accelerated approval for the treatment of certain patients with metastatic colorectal cancer.

A randomized phase 3 trial designed to compare an investigational combination with standard care for certain patients with advanced colorectal cancer failed to meet its primary endpoint of OS.

Sociodemographic factors may contribute to disparities in testing for two key biomarkers among patients with metastatic colorectal cancer, according to study results.

The FDA granted accelerated approval adagrasib with cetuximab for the treatment of KRASG12C -mutated locally advanced or metastatic colorectal cancer, according to a press release from the agency.

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

MADRID — Remarkable. Highly meaningful. Monumental.

MADRID — Sotorasib plus panitumumab prolonged PFS compared with standard of care for patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer, study results presented at ESMO Congress showed.

The FDA approved trifluridine and tipiracil with bevacizumab for patients with previously treated metastatic colorectal cancer.

Treatment with fruquintinib resulted in a significant and clinically meaningful survival benefit when compared with placebo among patients with refractory metastatic colorectal cancer, according to data published in The Lancet.